A single dose, cross-over pharmacokinetic study comparing oral formulations of BNC210 in healthy male volunteers
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2018
At a glance
- Drugs BNC 210 (Primary)
- Indications Agitation; Anxiety disorders; Post-traumatic stress disorders
- Focus Pharmacokinetics
- Sponsors Bionomics
- 05 Dec 2018 Status changed from Active not recruiting to completed.
- 08 Aug 2018 Planned End Date changed from 2 Aug 2018 to 9 Aug 2018.
- 19 Jul 2018 New trial record